Head-to-head · free
Pfizer vs Toyota Motor Corporation
PFE vs TM — return on capital, cash generation, margins and balance sheet side by side.
PFE
3 / 4
measures where PFE leads
TM
1 / 4
measures where TM leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | PFE · FY2025 | TM |
|---|---|---|
| Revenue | $62.6B | — |
| Net income | $7.8B | — |
| Revenue growth (yearly, multi-year) | -6.3% | — |
| Free cash flow | $9.1B | — |
| Free cash flow margin | 14.5% | — |
| Net cash / (debt) | — | — |
| ROIC | — | 3.6% |
| Return on equity | 8.9% | 10.1% |
| Gross margin | 74.3% | 16.7% |
| Operating margin | 27.8% | 7.4% |
| Net debt / EBITDA | 4.23x | 4.84x |
Figures are as reported by each company; latest fiscal year shown.
Where Pfizer's cash went (FY2025)
- Capital spending
- $2.6B
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free